Budesonide / Formoterol: 4 agencies, 2004–2024
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused budesonide / formoterol: all 14 decisive outcomes across 3 agencies were positive or positive with restrictions.
The file has been open for more than a decade: 20 years separate the first record, 10 May 2004 at SMC (Scotland), from the most recent, 13 May 2024 at SMC (Scotland).
SMC (Scotland) changed its position: recommended on 10 May 2004, restricted by 13 May 2024.
No assessment is on file from PHARMAC (New Zealand), TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for budesonide / formoterol, 1 submission was never made — an outcome set by the company rather than the assessor.
The file is active: 3 of 22 records date from 2023 or later.
The programme is broad: 11 distinct indication wordings are recorded for budesonide / formoterol by the agencies that label one in English (AWMSG, PBAC and SMC).
4 of these 22 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
SMC (Scotland) was first to assess budesonide / formoterol, on 10 May 2004; PBAC (Australia) did not open a file until 2017 — an unusually long tail of 13.2 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 12 years in total.
4 of the 4 agencies here assessed budesonide / formoterol more than once, HAS (France) most often at 9 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed budesonide / formoterol.
The full ledger for budesonide / formoterol reads 13 recommended, 5 not assessed, 2 other and 1 restricted, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| SMC (Scotland) | 13 May 2024 | Symbicort Turbohaler 200/6 as reliever therapy for adults and adolescents ≥12 years with mild asthma | accepted (restricted) | source |
| PBAC (Australia) | 2023 | Asthma Chronic obstructive pulmonary disease (COPD) | Recommended | source |
| HAS (France) | 4 Jan 2023 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| AWMSG (Wales) | 2 Dec 2021 | In adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticoster… | outside AWMSG criteria | source |
| HAS (France) | 4 Jul 2007 | Change to listing conditions (Transparency Committee) | ASMR V | source |
17 further decisions for budesonide / formoterol, across 4 agencies, are not shown here. They link to 11 further source documents.
Related molecules
- salbutamol — same ATC class R03A — Obstructive airway diseases
- formoterol — same ATC class R03A — Obstructive airway diseases
- indacaterol — same ATC class R03A — Obstructive airway diseases
- terbutaline — same ATC class R03A — Obstructive airway diseases
- fluticasone / salmeterol — same ATC class R03A — Obstructive airway diseases
- olodaterol / tiotropium — same ATC class R03A — Obstructive airway diseases
Coverage: 22 decisions for budesonide / formoterol from 4 agencies, 2004 to 2024. Data to 7 Sep 2026. ATC class R03A — Obstructive airway diseases. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.